Psoriasis comorbidities: complications and benefits of immunobiological treatment*
During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the deve...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193190/ |
| id |
pubmed-5193190 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-51931902016-12-29 Psoriasis comorbidities: complications and benefits of immunobiological treatment* de Carvalho, André Vicente Esteves Romiti, Ricardo Souza, Cacilda da Silva Paschoal, Renato Soriani Milman, Laura de Mattos Meneghello, Luana Pizarro Review During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients. Sociedade Brasileira de Dermatologia 2016 /pmc/articles/PMC5193190/ /pubmed/28099601 http://dx.doi.org/10.1590/abd1806-4841.20165080 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
de Carvalho, André Vicente Esteves Romiti, Ricardo Souza, Cacilda da Silva Paschoal, Renato Soriani Milman, Laura de Mattos Meneghello, Luana Pizarro |
| spellingShingle |
de Carvalho, André Vicente Esteves Romiti, Ricardo Souza, Cacilda da Silva Paschoal, Renato Soriani Milman, Laura de Mattos Meneghello, Luana Pizarro Psoriasis comorbidities: complications and benefits of immunobiological treatment* |
| author_facet |
de Carvalho, André Vicente Esteves Romiti, Ricardo Souza, Cacilda da Silva Paschoal, Renato Soriani Milman, Laura de Mattos Meneghello, Luana Pizarro |
| author_sort |
de Carvalho, André Vicente Esteves |
| title |
Psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| title_short |
Psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| title_full |
Psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| title_fullStr |
Psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| title_full_unstemmed |
Psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| title_sort |
psoriasis comorbidities: complications and benefits of
immunobiological treatment* |
| description |
During the last decade, different studies have converged to evidence the high
prevalence of comorbidities in subjects with psoriasis. Although a causal
relation has not been fully elucidated, genetic relation, inflammatory pathways
and/or common environmental factors appear to be underlying the development of
psoriasis and the metabolic comorbidities. The concept of psoriasis as a
systemic disease directed the attention of the scientific community in order to
investigate the extent to which therapeutic interventions influence the onset
and evolution of the most prevalent comorbidities in patients with psoriasis.
This study presents scientific evidence of the influence of immunobiological
treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept
and ustekinumab) on the main comorbidities related to psoriasis. It highlights
the importance of the inflammatory burden on the clinical outcome of patients,
not only on disease activity, but also on the comorbidities. In this sense,
systemic treatments, whether immunobiologicals or classic, can play a critical
role to effectively control the inflammatory burden in psoriatic patients. |
| publisher |
Sociedade Brasileira de Dermatologia |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193190/ |
| _version_ |
1613834971505491968 |